Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model

Similar Items

• Reply to Hunsberger and Memoli, “Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat”
  od: McBride, Jacqueline M., i dr.
  Izdano: (2017)
• Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
  od: Deng, Rong, i dr.
  Izdano: (2020)
• Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers
  od: Lim, Jeremy J., i dr.
  Izdano: (2016)
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection
  od: Lim, Jeremy J., i dr.
  Izdano: (2020)
• Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A
  od: Gupta, Priyanka, i dr.
  Izdano: (2016)